欧洲疾病预防控制中心《百日咳鲍特菌的实验室诊断和分子监测》解读  

Interpretation of laboratory diagnosis and molecular surveillance of Bordetella pertussis published by Euro-pean Centre for Disease Prevention and Control

作　　者：胡亚红 姚开虎 Hu Yahong;Yao Kaihu(Key Laboratory of Major Diseases in Children,Ministry of Education,National Clinical Medical Research Center for Respiratory Diseases,Laboratory of Microbiology,Beijing Pediatric Research Institute,Beijing Children′s Hospital,Capital Medical University,National Center for Children′s Health,Beijing 100045,China)

机构地区：[1]国家儿童医学中心,首都医科大学附属北京儿童医院,北京市儿科研究所微生物研究室,国家呼吸系统疾病临床医学研究中心,教育部儿科重大疾病研究重点实验室,北京100045

出　　处：《中华实用儿科临床杂志》2023年第10期755-759,共5页Chinese Journal of Applied Clinical Pediatrics

基　　金：国家自然科学基金(81973100);国家呼吸系统疾病临床医学研究中心呼吸专项(HXZX-202106)。

摘　　要：百日咳是一种极具传染性的急性呼吸道感染性疾病,尽管已广泛开展了儿童疫苗接种,但并不能由此获得终身免疫。为应对百日咳在世界流行的挑战,2022年12月21日欧洲疾病预防控制中心发布了《百日咳鲍特菌的实验室诊断和分子监测》,详细描述了百日咳实验室诊断和分子监测的方案,值得我国从事百日咳诊疗的医护人员和技术人员研究学习,现介绍并解读该文件的主要内容。Pertussis is a highly contagious acute respiratory infection.Although childhood vaccination has been widely practiced,it does not result in lifelong immunity.On December 21,2022,aiming to meet the challenge of pertussis epidemic in the world,European Centre for Disease Prevention and Control published laboratory diagnosis and molecular surveillance of Bordetella pertussis,which describes in detail the protocols for laboratory diagnosis and molecular technology for pertussis,and it is worthwhile to study and learn from healthcare professionals and technicians engaged in the field of diagnosis and treatment of pertussis disease in China.This article introduces and interprets the main contents of the document.

关 键 词：百日咳鲍特菌 实验室诊断 分子监测 

分 类 号：R725.6[医药卫生—儿科]